CareDx reported validation data from the ACROBAT observational study supporting AlloHeme, its cell‑free DNA assay for allogeneic hematopoietic cell transplant surveillance. AlloHeme achieved 85% sensitivity and 92% specificity in the analysis and detected molecular relapse with a median lead time of 41 days compared with clinical relapse. The company plans to publish the ACROBAT data and prepare for a commercial launch next year; executives emphasized the assay’s potential to supplant some invasive bone‑marrow testing and to inform earlier preemptive interventions. The findings were presented with commentary from study co‑investigators at Columbia and other academic centers. Source: CareDx investor presentation and ACROBAT study results.